| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-11-02 | Infinity Pharmaceuticals (USA - MA) Verastem (USA - MA) | duvelisib (IPI-145) | hematologic cancers, including chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (iNHL) and T cell lymphomas | licensing |
Cancer - Oncology | Licensing agreement |
| 2016-11-02 | Targovax (Norway) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-11-01 | Bayer Healthcare (Germany) Ionis Pharmaceuticals (USA - CA) | IONIS-FXIRx | prevention of thrombosis | licensing |
Cardiovascular diseases | Milestone |
| 2016-10-31 | BioTime (USA - CA) | nomination |
Nomination | |||
| 2016-10-31 | Epizyme (USA - MA) National Cancer Institute (USA) | tazemetostat - EPZ-6438 (E7438), pinometostat | hematologic malignancies, solid tumors including ovarian cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-10-27 | Erytech Pharma (France) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2016-10-27 | Clovis Oncology (USA - CO) Lonza (Switzerland) | rucaparib | ovarian cancer | manufacturing bioproduction |
Cancer - Oncology | Production agreement |
| 2016-10-26 | Pieris (Germany) Daiichi Sankyo (Japan) | Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets | collaboration licensing | Milestone | ||
| 2016-10-26 | Active Biotech (Sweden) NeoTX (Israel) | ANYARA (naptumomab estafenatox) | licensing development commercialisation |
Cancer - Oncology | Licensing agreement | |
| 2016-10-26 | Nordic Nanovector (Norway) Heidelberg Pharma (Germany) | antibody-drug conjugates for treating leukemias | leukemia | development |
Cancer - Oncology | Development agreement |
| 2016-10-26 | Allergan (Ireland) | nomination |
Nomination | |||
| 2016-10-26 | Merus (The Netherlands) | nomination | Cancer - Oncology | Nomination | ||
| 2016-10-25 | NeuroVive Pharmaceutical (Sweden) Hospices Civils de Lyon (France) | termination of an agreement |
Cardiovascular diseases - Cerebrovascular diseases | Termination of an agreement | ||
| 2016-10-25 | Myriad RBM, a wholly-owned subsidiary of Myriad Genetics (USA - UT) Sanofi (France) | biomarker analysis | prediction of cardiovascular and microvascular (renal and retinal) risk in people with type 2 diabetes | collaboration |
Cardiovascular diseases - Metabolic diseases | Collaboration agreement |
| 2016-10-25 | Relief Therapeutics (Switzerland) FirstString Research (USA - CA) | atexakin alfa | diabetic neuropathy | development |
Mental diseases - CNS diseases | Development agreement |
| 2016-10-24 | Solid Biosciences (USA - MA) Solid GT (USA - MA) | establishment of a new subsidiary in the EU |
Rare diseases - Genetic diseases - Neuromuscular diseases | Establishment of a new subsidiary in the EU | ||
| 2016-10-24 | Solid Biosciences (USA - MA) Solid GT (USA - MA) | establishment of a new subsidiary in the EU |
Rare diseases - Genetic diseases - Neuromuscular diseases | Establishment of a new subsidiary in the EU | ||
| 2016-10-24 | Solid Biosciences (USA - MA) Solid GT (USA - MA) | establishment of a new subsidiary in the EU |
Rare diseases - Genetic diseases - Neuromuscular diseases | Establishment of a new subsidiary in the EU | ||
| 2016-10-24 | Solid Biosciences (USA - MA) Solid GT (USA - MA) | establishment of a new subsidiary in the EU |
Rare diseases - Genetic diseases - Neuromuscular diseases | Establishment of a new subsidiary in the EU | ||
| 2016-10-24 | Solid Biosciences (USA - MA) Solid GT (USA - MA) | establishment of a new subsidiary in the EU |
Rare diseases - Genetic diseases - Neuromuscular diseases | Establishment of a new subsidiary in the EU |
